NuGen secures $930K debt facility from CEO-controlled lender
What's the deal? NuGen Medical DevicesDealroom has a profile for this one. Try Dealroom →, a Toronto-listed maker of needle-free drug delivery systems, has entered a loan agreement for up to US$953.3K with Sol-Millennium Medical HK LimitedDealroom has a profile for this one. Try Dealroom →. The debt facility, dated September 18, 2026, carries a 6% annual interest rate and matures five years from the initial advance.
How it's structured: NuGen receives an initial advance of US$366.7K once conditions are met. The remaining US$586.7K follows the signing of a definitive agreement to acquire Sol-Millennium Canada Inc.Dealroom has a profile for this one. Try Dealroom →, a deal NuGen first announced on August 6, 2026.
What's the money for? Proceeds will cover costs tied to the proposed acquisition and working capital to keep operations running before and after the deal closes. The loan is secured against NuGen's assets under a general security agreement.
The related-party angle: The lender is owned and controlled by Liang Lin, NuGen's chief executive officer and a director. The transaction is a related party deal under Multilateral Instrument 61-101; Lin declared his conflict and abstained from board deliberations, and the loan was unanimously approved by the board.
What could go wrong? If NuGen misses a payment, overdue amounts accrue interest at 12% per year. The company must also prepay the loan from proceeds of any major liquidity event exceeding $1 million, including asset sales, financings, or a change of control.
The signal: The sum is modest — landing near the bottom of comparable rounds by amount. But it underscores a familiar reality for small-cap medical device firms: tapping insider capital to bridge an acquisition when broader markets are out of reach. NuGen's flagship InsuJet system is approved in 42 countries, and this facility is a bet that consolidation, funded from within, can extend its runway.
Image credit: Generated with Gemini
